All News
Filter News
Found 297 articles
-
Fulcrum Therapeutics® to Participate at Upcoming November 2022 Investor Conferences
11/1/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.
-
World Muscle Society Congress 2022: Genentech, Fulcrum and Sarepta Present Latest Findings
10/12/2022
The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look. -
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
10/12/2022
Fulcrum Therapeutics, Inc announced today that new data from the open label extension (OLE) portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society (WMS) Hybrid Congress taking place October 11-15 in Halifax, Canada.
-
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022
10/7/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to a new employee as inducement awards outside of the Company’s 2019 Stock Incentive Plan.
-
Beyond the usual challenge of delivering high-quality data that answers meaningful questions, PepGen's Michelle Mellion is dedicated to “incorporating the patient’s voice into everything we do.”
-
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 09, 2022
9/9/2022
Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.
-
Fulcrum Therapeutics to Participate at Upcoming September 2022 Investor Conferences
9/6/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.
-
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
8/25/2022
HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff , PhD, as interim chief executive officer.
-
Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH
8/17/2022
Sonoma Biotherapeutics, Inc. today announced the appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH, to its Board of Directors.
-
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock - Aug 16, 2022
8/16/2022
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share.
-
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
8/16/2022
Fulcrum Therapeutics, Inc. today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET.
-
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock - Aug 15, 2022
8/15/2022
Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $75 million of shares of its common stock.
-
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
8/11/2022
Fulcrum Therapeutics, Inc.® today reported financial results for the second quarter of 2022 and announced a strategic plan to realign internal resources to support the two clinical programs that are expected to be the key drivers of near-term value and extend cash runway.
-
NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team
8/11/2022
NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer.
-
Five years after joining Johnson & Johnson as head of research and development, Mathai Mammen is leaving abruptly to seek other opportunities outside the company.
-
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
8/4/2022
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open.
-
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022
8/2/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.
-
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
7/28/2022
Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery.
-
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
-
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 15, 2022
7/15/2022
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.